US 2022/0064301 A1Published application

Anti-ctla4 antibodies and methods of use thereof

AssigneeXilio Development, Inc.

InventorMargaret Karow

Life of this patent

Estimating the term…

Abstract

The invention provides anti-CTLA4 binding proteins (e.g., antibodies, bispecific antibodies, and chimeric receptors) and their use in treating and preventing cancer, as well as compositions and kits comprising the anti-CTLA4 binding proteins.

Claims55

Dependent claims

An anti-CTLA4 antibody or antigen-binding fragment thereof comprising a light chain variable (VL) domain and a heavy chain variable (VH) domain, wherein:

a) the VL domain comprises (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
1, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
2, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
3;
and/or the VH domain comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
4, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
5, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
6;
or
b) the VL domain comprises (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
13, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
14, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
15;
and/or the VH domain comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
16, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
17, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
18;
or
c) the VL domain comprises (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
7, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
8, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
9;
and/or the VH domain comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
10, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
11, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
12;
or
d) the VL domain comprises (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
19, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
20, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
21;
and/or the VH domain comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
22, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
23, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
24.

32 more elements

A bispecific antibody or an antigen-binding fragment thereof, comprising

1) a light chain and a heavy chain of a first pair that specifically binds to CTLA4;
2) a light chain and a heavy chain of a second pair that specifically binds to an antigen;
wherein the light chain of the first pair comprises a VL domain, and the heavy chain of the first pair comprises a VH domain and wherein:
a) the VL domain comprises (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
1, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
2, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
3;
and/or the VH domain comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
4, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
5, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
6;
or
b) the VL domain comprises (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
13, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
14, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
15;
and/or the VH domain comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
16, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
17, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
18;
or
c) the VL domain comprises (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
7, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
8, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
9;
and/or the VH domain comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
10, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
11, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
12;
or
d) the VL domain comprises (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
19, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
20, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
21;
and/or the VH domain comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
22, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
23, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
24.

35 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/417,244Filed 26 Dec 2019
Priority: 26 Dec 2018
Published: 3 Mar 2022
Term ends: Not estimatedThe source records don’t support an estimate.

Classification19 codes

C07K 16/2818
Against the immunoglobulin superfamily: against CD28 or CD152
A61K 47/6849
The modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site: the antibody targeting a receptor, a cell…
A61P 35/00
Antineoplastic agents
C07K 14/70521
Immunoglobulin superfamily: cd28, cd152

Family

Application62/785,111Us provisional application · filed 26 Dec 2018
US 12,435,142 B2Related patent
US 2022/0064301 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

An anti-CTLA4 antibody or antigen-binding fragment thereof comprising a light chain variable (VL) domain and a heavy chain variable (VH) domain, wherein:

a) the VL domain comprises (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
1, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
2, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
3;
and/or the VH domain comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
4, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
5, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
6;
or
b) the VL domain comprises (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
13, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
14, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
15;
and/or the VH domain comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
16, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
17, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
18;
or
c) the VL domain comprises (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
7, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
8, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
9;
and/or the VH domain comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
10, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
11, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
12;
or
d) the VL domain comprises (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
19, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
20, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
21;
and/or the VH domain comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
22, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
23, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
24.

32 more elements

Facts

Application

17/417,244Filed 26 Dec 2019

Priority

26 Dec 2018

Published

3 Mar 2022

Term ends

Not estimatedThe source records don’t support an estimate.

Classification19 codes

C07K 16/2818
Against the immunoglobulin superfamily: against CD28 or CD152
A61K 47/6849
The modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site: the antibody targeting a receptor, a cell…
A61P 35/00
Antineoplastic agents
C07K 14/70521
Immunoglobulin superfamily: cd28, cd152